David Fairlamb, Director of Regulatory Affairs, SolasCure, UK
David has more than 30 years of global regulatory affairs experience working in industry and consultancy supporting small molecule, biologics, medical devices and combination product development.
At SolasCure, David has shown exceptional leadership in developing and managing a changing regulatory strategy as well as regulatory operational activities to support the development of a novel investigational medicinal product – Aurase Wound Gel – a hydrogel containing a recombinant enzyme cloned from medical maggots that has the potential to support healthcare professionals treating patients with chronic wounds.
The Futures Award acknowledges the role of regulatory scientists in realising the potential of cutting edge technologies, such as those involving medical devices, advanced therapies and innovative medicines and their delivery systems. Such advances help bring innovative treatments to patients faster by embracing Scientific Advice and combining a flexible and professional approach to certification and licensing with excellence in quality management and benefit-risk assessment. This Award focuses on new products and innovative technologies that provide a significant advance in healthcare techniques and improve the delivery and efficacy of existing therapies.